Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Robin Park(Moffitt Cancer Center), Christine H. Chung(Moffitt Cancer Center), Joaquim M. Farinhas(Moffitt Cancer Center), Kedar Kirtane(Moffitt Cancer Center), Jamie K. Teer(University of Virginia), Jason Tasoulas(University of North Carolina at Chapel Hill), Ritu Chaudhary(Moffitt Cancer Center), Maria I. Poole(Moffitt Cancer Center), Xiaofei Song(Moffitt Cancer Center), MacLean S. Hall(Moffitt Cancer Center), Jiannong Li(Moffitt Cancer Center), Carina Ferraris(Nova Southeastern University), Robbert J.C. Slebos(University of Iowa), Juan Hernandez-Prera(Moffitt Cancer Center), Antonio L. Amelio(University of North Carolina at Chapel Hill)
Cited by 5
Related Papers
Proteogenomic characterization of human colon and rectal cancer
|Nature|2014|1.6k
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
|New England Journal of Medicine|2008|1.5k
Glucose-Independent Glutamine Metabolism via TCA Cycling for Proliferation and Survival in B Cells
|Cell Metabolism|2012|1.1k